
Halozyme Therapeutics, Inc.: A biotech firm innovating in diabetes, cancer, dermatology, and drug delivery.
Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative products for the diabetes, cancer, dermatology, and drug delivery markets. Founded in 1998 and headquartered in San Diego, California, Halozyme leverages its proprietary recombinant human hyaluronidase platform technology to enhance drug delivery and efficacy. The company collaborates with pharmaceutical partners to apply its technology across various therapeutic areas, aiming to improve patient outcomes and ease the burden of treatment.
Halozyme has made significant strides in the biotech industry, becoming a publicly traded company on Nasdaq under the ticker HALO and a component of the S&P 400. Its disruptive drug delivery technologies have garnered attention for their potential to transform patient care. The company's commitment to innovation and patient-centric solutions has solidified its reputation as a leader in the biopharmaceutical sector.

Zenomics

Heron Therapeutics
herontx.com

Denali Therapeutics

Gyre Therapeutics

Extend Biosciences
extendbio.com

InSitu Biologics

Enable Therapeutics

BridgeBio Pharma
bridgebio.com

LayerBio
layerbio.com

Nurix
nurixtx.com

Kyntra Bio
fibrogen.com

Genentech
gene.com

Zymeron
zymeron.com

Halia Therapeutics

Halda Therapeutics
haldatx.com
Companies similar to Halozyme Therapeutics include Zenomics, Heron Therapeutics, Denali Therapeutics and Gyre Therapeutics.
Halozyme Therapeutics was founded in 1998.
Halozyme Therapeutics' headquarters is located in San Diego, CA, US.
Halozyme Therapeutics' most recent funding round was for $500M (USD) in August 2022.
As of Aug 15, 2022, Halozyme Therapeutics has raised a total of $745M (USD).
Halozyme Therapeutics has 393 employees as of Feb 6, 2024.